Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, February 28, 2023
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
[ Tue, Feb 28th 2023
] - WOPRAI
Matthew Harrison Maintained (BGNE) at Buy with Decreased Target to $321 on, Feb 28th, 2023
Matthew Harrison of Morgan Stanley, Maintained "BeiGene, Ltd." (BGNE) at Buy with Decreased Target from $325 to $321 on, Feb 28th, 2023.
Matthew has made no other calls on BGNE in the last 4 months.
There is 1 other peer that has a rating on BGNE. Out of the 1 peers that are also analyzing BGNE, 0 agree with Matthew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Matthew
- Andrew Berens of "SVB Leerink" Maintained at Buy with Increased Target to $300 on, Friday, January 20th, 2023
